C Ray Therapeutics Highlights China-Based IIT Model to Accelerate Radiopharmaceutical Development

According to a recent LinkedIn post from C Ray Therapeutics, the company is emphasizing China’s Investigator-Initiated Trial (IIT) framework as a strategic route to accelerate radiopharmaceutical development. The post links heightened global interest in the IIT model to discussions at the recent JPM Healthcare Conference and an FDA cell and gene therapy roundtable, where dual-track approaches were reportedly highlighted.

The post suggests that IITs are attracting attention because radiopharmaceuticals face high translational uncertainty and complex dose selection, increasing the value of early human biodistribution and dosimetry data. It also indicates that investors and global partners are seeking earlier human data as de-risking signals before committing capital to large-scale clinical programs, positioning IITs as a potential decision-support tool.

As shared in the post, C Ray Therapeutics portrays itself as an early mover in applying IITs to next-generation radiopharmaceuticals, citing timelines of 6–9 months from formulation to first-in-human studies, more than 150 enrolled subjects, and over 10 IIT clinical sites across China. If accurate, these metrics could indicate a relatively capital-efficient path to early clinical validation, which may be relevant for investors evaluating the company’s development velocity and risk profile.

The LinkedIn update also notes that the firm’s Senior Director of BD, Andrew Li, is scheduled to speak on a panel at the TRP Target Selection & Drug Design Summit in Boston about using IITs to remove Phase Zero obstacles. Visibility at such industry forums may support C Ray Therapeutics’ positioning within the radiopharmaceutical ecosystem and could facilitate potential business development or partnership discussions, particularly with parties interested in leveraging China-based IIT infrastructure.